5 completed, 2 terminated. 5 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 5 |
| Phase 2 | 2 | Terminated 2 |
Follow izencitinib: new trials by email Literature Review of izencitinib trials Research Report on izencitinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Single Dose Bioavailability and Ethnobridging PK Study in Healthy Subjects TD-1473 [Tablet A], TD-1473 [Tablet B] - Intestinal Disorder, Bowel Diseases, Inflammatory | Phase 1 | Completed | Theravance Biopharma | 58 | 2020-10-16 | 2021-04-09 |
| Rifaximin in Patients With Diabetic Gastroparesis Rifaximin, Placebo - Crohn Disease, Diabetic Gastroparesis | Phase 2 | Terminated | Mayo Clinic | 5 | 2019-06-14 | 2026-06-22 |
| Efficacy and Safety of TD-1473 in Crohn's Disease Placebo, TD-1473 - Crohn's Disease | Phase 2 | Terminated | Theravance Biopharma | 167 | 2018-11-19 | 2023-03-13 |
| Food-effect, Drug-Drug Interaction (DDI), and Formulation Bridging Study TD-1473, Itraconazole - Inflammatory Bowel Disease | Phase 1 | Completed | Theravance Biopharma | 36 | 2018-06-13 | 2021-01-14 |
| TD-1473 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male Subjects TD-1473 oral capsule, [14C]-TD-1473 IV bolus, [14C]-TD-1473 Oral Capsule - Intestinal Disorders, Bowel Diseases, Inflammatory | Phase 1 | Completed | Theravance Biopharma | 20 | 2018-01-31 | 2021-01-14 |
| TD-1473 for Active Ulcerative Colitis (UC) TD-1473, Placebo - Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe | Phase 1 | Completed | Theravance Biopharma | 40 | 2016-10-03 | 2021-09-30 |
| SAD and MAD Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of TD-1473 in Healthy Subjects TD-1473 for SAD, Placebo for SAD, TD-1473 for MAD - Healthy | Phase 1 | Completed | Theravance Biopharma | 72 | 2015-12-01 | 2021-01-19 |
Inflammatory Bowel Diseases (4) · Crohn Disease (2) · Intestinal Diseases (2) · Colitis, Ulcerative (1) · Irritable Bowel Syndrome (1)
Theravance Biopharma (6) · Mayo Clinic (1)
United States (7) · Georgia (2) · Romania (2) · Australia (1) · Austria (1) · Bulgaria (1) · Croatia (1) · France (1) · Germany (1) · Greece (1) · Hungary (1) · Israel (1) · Moldova (1) · New Zealand (1) · Poland (1)
Brian E Lacy (1)
2016 (1), 2018 (1)